PDS Biotechnology Corp (NASDAQ:PDSB) — Market Cap & Net Worth
Market Cap & Net Worth: PDS Biotechnology Corp (PDSB)
PDS Biotechnology Corp (NASDAQ:PDSB) has a market capitalization of $16.40 Million ($16.40 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25815 globally and #5429 in its home market, demonstrating a 187.44% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PDS Biotechnology Corp's stock price $0.84 by its total outstanding shares 55971338 (55.97 Million). Also see total assets of PDS Biotechnology Corp for a full breakdown of the balance sheet.
PDS Biotechnology Corp Market Cap History: 2015 to 2026
PDS Biotechnology Corp's market capitalization history from 2015 to 2026. Data shows change from $13.99 Billion to $47.14 Million (-43.72% CAGR). Also see cash flow conversion of PDS Biotechnology Corp for how efficiently the company converts equity into cash flow.
Index Memberships
PDS Biotechnology Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #729 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2392 of 3165 |
Weight: PDS Biotechnology Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
PDS Biotechnology Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PDS Biotechnology Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check PDS Biotechnology Corp stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PDSB by Market Capitalization
Companies near PDS Biotechnology Corp in the global market cap rankings as of September 18, 2026. Review tangible equity quality of PDS Biotechnology Corp to assess the quality of the company's equity after excluding intangible assets.
Key companies related to PDS Biotechnology Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
PDS Biotechnology Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, PDS Biotechnology Corp's market cap moved from $13.99 Billion to $ 47.14 Million, with a yearly change of -43.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $47.14 Million | +9.41% |
| 2025 | $43.09 Million | -52.77% |
| 2024 | $91.23 Million | -67.20% |
| 2023 | $278.18 Million | -62.35% |
| 2022 | $738.82 Million | +62.96% |
| 2021 | $453.37 Million | +278.50% |
| 2020 | $119.78 Million | -19.25% |
| 2019 | $148.32 Million | -58.72% |
| 2018 | $359.34 Million | -96.57% |
| 2017 | $10.49 Billion | -25.04% |
| 2016 | $13.99 Billion | 0.00% |
| 2015 | $13.99 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of PDS Biotechnology Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.40 Million USD |
| MoneyControl | $16.40 Million USD |
| MarketWatch | $16.40 Million USD |
| marketcap.company | $16.40 Million USD |
| Reuters | $16.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are… Read more